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Abstract
Cancer is the leading cause of death among Asian Americans, and cancer cases among Asian 
Americans, Pacific Islanders, and Native Americans are expected to rise by 132% by 2050. Yet 
little is known about biologic and environmental factors that contribute to these higher rates of 
disease in this population. Precision medicine has the potential to contribute to a more 
comprehensive understanding of morbidity and mortality trends among Asian American 
subgroups and to reduce cancer-related health disparities by recognizing patients as individuals 
with unique genetic, environmental, and lifestyle characteristics; identifying ways in which these 
differences impact cancer expression; and developing tailored disease prevention and clinical 
treatment strategies to address them. Yet substantial barriers to the recruitment and retention of 
Asian Americans in cancer research persist, threatening the success of precision medicine research 
in addressing these knowledge gaps. This commentary outlines the major challenges to recruiting 
and retaining Asian Americans in cancer trials, suggests ways of surmounting them, and offers 
recommendations to ensure that personalized medicine becomes a reality for all Americans.
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Introduction
The global cancer burden is estimated to rise from 14 million new cases in 2012 to 24 
million in 2035.[1] Existing data demonstrate population-based disparities in cancer 
prevalence and survival rates that will expand as cancer cases increase.[2] In the United 
States (US), 31% increase in cancer incidence by 2050 is anticipated for whites, as 
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compared to a 99% or more increase in cancer cases among ethnic and racial minority 
groups, including American Indian/Alaska natives, African Americans, Latino/Hispanics, 
Asian Americans, Native Hawaiians, and Pacific Islanders. [3] Currently, among Asian 
Americans, Native Hawaiians, and Pacific Islanders, cancer is the leading cause of mortality, 
accounting for 27% of deaths [4]; and by 2050, cancer cases are expected to rise by 132%. 
[5]
Precision medicine has the potential to reduce these disparities. By recognizing patients as 
individuals with unique genetic, environmental, and lifestyle characteristics, precision 
medicine research aims to identify ways in which these differences impact cancer 
expression, and to develop tailored disease prevention and clinical treatment strategies.[6] 
The federal allocation of $215 million to the Precision Medicine Initiative (PMI) signals a 
national commitment to this emerging area. The PMI will support innovative, patient-
centered studies that explore individual variability in cancer expression, develop creative 
approaches to addressing variability, and rigorously test new strategies for controlling 
cancer. [7] The initiative’s discoveries may ultimately impact public health and clinical 
practice for a broad range of chronic diseases.
Importantly, the PMI will recruit and retain a research cohort of one million Americans,[8] 
offering an unprecedented opportunity to expand and diversify clinical trials to include 
individuals from a broad range of geographic regions, ethnic backgrounds, and lifestyles. [9] 
As such, not only may the PMI impact clinical cancer treatment by defining and targeting 
molecular mechanisms of disease, but also help to define effective public health strategies 
for high-risk populations. [2] In order to realize this promise, however, clinicians, 
researchers, and public health practitioners must work together to ensure that the recruitment 
and retention of a diverse million-person cohort is a success. Traditionally, US clinical trial 
participation has been dominated by whites; furthermore, populations with lower 
educational attainment and lower socioeconomic status (SES) have been under-represented. 
[9] As a result, new medicines and technologies that result from these trials may not meet 
the needs of many Americans. By contrast, the PMI challenges the research community to 
look beyond a “one size fits all” approach to cancer treatment and prevention, in order to 
provide the right service at the right time to the right people. [10]
This commentary will describe cancer among Asian Americans, share key findings that 
suggest deeper inquiry into sociodemographic, cultural, and biologic factors that impact 
cancer cases among various Asian American subgroups is needed, describe the challenges of 
recruiting and retaining Asian Americans in scientific research, and suggest ways of 
surmounting them. The objective is to contribute to the literature informing recruitment and 
retention of a sufficiently diverse cohort to ensure the PMI’s success.
Diversity of the Asian American population
Asian Americans comprise 5.6% of the U.S. population (14 million people), and are the 
fastest growing racial/ethnic minority group, expected to rise to 38 million people in 2050. 
[11] The term “Asian American” encompasses a diverse mix of people, including East 
Asians (e.g., Chinese, Japanese, Korean), Asian Indians (e.g., Bangladeshi, Indian, 
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Pakistani), and Southeast Asians (e.g., Filipinos, Cambodians, Thai, Vietnamese). These 
groups have distinct genetic traits, environmental exposures, and cultural histories that 
differentially impact their cancer risk profiles and the epidemiology of cancer expression. 
Cancer is the leading cause of death for most Asian American adults 25–64 years of age, 
[12] and for some types of cancers, Asian Americans have the lowest screening rates and the 
highest proportion of late-stage diagnoses. [13]
Over 60 nationalities that speak over 100 languages may be grouped into one US Census 
category (“Asian American/Pacific Islander”), masking marked differences in demographic 
characteristics that are known to be associated with cancer risk factors. For example, low 
English proficiency (LEP), which is defined as the inability to speak, read, write, or 
understand English “very well,” impacts only 10% of Filipino Americans, but affects 45% of 
Vietnamese Americans.[14] Poverty rates among Asian American subgroups are similarly 
disparate. While Japanese Americans have the same 6.6% poverty rate that has been 
documented among whites, the poverty rate among Southeast Asians is 66.6%. [13] Stark 
differences in household income, educational attainment, and language ability have also 
been documented within subgroups. For instance, South Asians -- a diverse subgroup that 
includes Indians, Pakistanis, Bangladeshis, Sri Lankans, Nepalis, and Bhutanese -- have a 
median household income of $72,000/year, substantially higher than the US average of 
$53,000/year. Yet, within that group, Bangladeshi Americans have a median income of only 
$46,950/year, while Indian Americans have a median income of $95,000. [15]
Factors impacting cancer disparities among Asian Americans
Sociodemographic factors
Poverty, low educational attainment, and LEP are linked to health disparities among racial/
ethnic minority groups, in general. [16] Higher cancer mortality rates among immigrant 
groups, including Asian Americans, have been attributed more specifically to a lack of 
access to health care, lack of cancer education and awareness, and institutional barriers 
associated with LEP, low SES, and cultural beliefs that may be at odds with public health 
messaging about cancer prevention and treatment. [17] For example, research has shown that 
some Asian Americans believe cancer is a punishment for immoral behavior [17]; and 
studies have demonstrated that individuals of Asian American descent may resist prioritizing 
cancer screening and treatment because they viewed their personal well-being as less 
important than their families’ welfare. [5] Furthermore, among some Asian American 
groups, fatalistic views about health in general – and cancer diagnoses in particular - may 
conflict with public education campaigns or even provider advice to screen for infectious 
origin. [18]
This is particularly concerning because Asian Americans experience proportionally more 
cancers of infectious origin than other racial/ethnic groups, including human papillomavirus 
(HPV)-induced cervical cancer, hepatitis B virus (HBV)-induced liver cancer, and stomach 
cancer. [11, 19] The screening programs that have significantly improved detection and 
treatment of these cancers among the general US population remain underused by Asian 
American groups due to a lack of linguistically- and culturally-tailored programming for 
Asian Americans. As a result, Asian Americans have the lowest rates of Pap smear/cervical 
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cancer screening (68%) as well as endoscopy/stomach cancer screening (19%) of any US 
ethnic/racial group [18] Acknowledging and addressing differences in Asian American care-
seeking practices and health beliefs through tailored messaging and education, along with 
increasing access to preventive care among Asian Americans through the development of 
linguistically-appropriate, conveniently-located, and affordable services, is imperative to 
improving these rates.
Biologic factors
Biologic factors also contribute to differences in cancer rates among Asian American 
subgroups, and between Asian Americans and other racial/ethnic minority groups. 
Identifying Asian Americans by known genetic differences, and targeting cancer prevention 
strategies and treatments toward their profiles could vastly improve outcomes. For example, 
a unique loss-of-function point mutation in aldehyde hydrogenase 2 (ALDH2), referred to as 
ALDH2*2, affects 560 million people of East Asian descent globally. [20] Studies suggest 
that ALDH2*2 reduces the ability of ALDH2 to catalyze the oxidation of toxic cellular 
aldehydes, contributing to an increased risk of oral cancer and gastrointestinal cancer, among 
other illnesses. Moreover, the presence of ALDH2*2 may compromise the effectiveness of 
certain medications. Examples include nitroglycerin, which may be less effective in reducing 
vasodilation among individuals with ALDH2*2 experiencing acute myocardial infarction, 
and acetaminophen, which may be detrimental to preserving tissue following ischemic 
injury among patients with ALDH2*2. Thus, screening individuals of East Asian descent for 
ALDH2*2 using either a simple two-question screener or a rapid genotyping test could help 
health care providers to develop both personalized preventive care plans as well as treatment 
plans for their patients who test positive for the mutation. Additional research into the 
activation of ALDH2*2, leading to treatments based on this genotype, could substantially 
improve clinical care and cancer outcomes for Asian Americans.
As another example, studies of lung cancer have identified the higher incidence of activated 
epidermal growth factor receptor mutations among Chinese patients as compared to other 
groups. [2] This higher incidence may contribute to the higher rates of lung cancer seen in 
China as compared to the US, particularly among non-smokers and women; it may also 
explain why Chinese Americans experience the highest lung cancer mortality rate of all 
Asian American subgroups, despite having lower incidence rates than other groups. 
However, a lack of sufficiently powered studies has precluded researchers from suggesting 
how best to test for these mutations and tailor clinical care for Chinese American patients 
that manifest them. Precision medicine has the opportunity to correct this imbalance by 
including Asian Americans in studies that aim to identify, understand, and target disease-
modifying molecular mutations, as a critical step toward developing therapies for resistant 
subpopulations of tumors. [10]
Barriers to Asian American Participation in Cancer Research
Despite the passage of the federal Revitalization Act in 1993 to ensure that federally funded 
clinical research prioritized the inclusion of racial/ethnic minorities and women, less than 
2% of 10,000 federally funded cancer clinical trials since that year have met the federal 
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government’s own guidelines for diversification of participant cohorts in cancer research. 
[21] Cancer clinical trials have rarely included sufficient numbers of Asian Americans or 
other racial/ethnic minority populations to allow scientists to develop a complete picture of 
the biologic, sociodemographic, and environmental factors influencing cancer expression. 
[9] For instance, the Multi-ethnic Cohort Study for cancer included only Japanese 
Americans, excluding all other Asian American groups, and thus limiting the 
generalizability of findings.[22] The absence of Asian Americans in cancer clinical trials 
reflects a more generalized challenge facing health research: Asian Americans are the most 
understudied of all racial/ethnic minority groups, overlooked in national health surveys and, 
consequently, the clinical research informed by them. [14]
Inadequate data collection strategies and methods
Inaccurate estimations of disease risk for Asian Americans result from biases within data 
collection methods. Examples include the limited availability of Asian languages for survey 
administration, which prevents many Asian Americans from participating in surveys due to 
LEP; and the use of random digit dialing sampling methods, which often include only 
landlines and thus have been shown to exclude many immigrant communities, including 
Asian Americans. Additionally, surveys may suffer from a lack of geographic 
representation, which translates to underrepresentation of Asian Americans in national 
datasets. For example, the Surveillance, Epidemiology, and End Results (SEER) registry is 
the only federally-funded national dataset of cancer incidence in the US; but the SEER 
registry does not conduct data collection in every state, resulting in unbalanced datasets. For 
instance, New York, a state with one of the largest and most diverse Asian American 
populations in the country, does not have a SEER registry site. [14]
Some surveys omit Asian Americans from data collection altogether, while others aggregate 
health data for all subgroups, or extrapolate risk for all Asian Americans from data collected 
from only one or several subgroups. [22] These practices have led to the systematic 
underrepresentation of Asian Americans in national and regional surveys, and the 
minimization of Asian American health disparities. Yet, solutions to these challenges are 
available. A number of innovative and feasible strategies have been proposed, [14] 
including:
• Pooling data across years in order to develop a sufficiently large dataset of Asian 
Americans for analysis;
• Using innovative sampling strategies, such as oversampling, targeted sampling, 
respondent-driven sampling, cumulations, and add-ons;
• Engaging health plans, disease registries, hospitals, and other providers to create 
community-based epidemiological data repositories;
• Collecting granular data, including country of birth and number of years in the 
US, to allow for detailed analysis of epidemiologic trends; and
• Utilizing community-based participatory research models (CBPR) or other 
community-engaged methods, and developing mixed methods approaches.
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Multilevel socioecological barriers to Asian American participation
Barriers at the societal, systemic, provider, and individual level also impact Asian American 
participation in health research; yet, like data-related issues, these barriers also may be 
overcome with focused efforts. At the societal level, the pervasive “model minority” 
stereotype – that is, the misconception that all Asian Americans are highly educated, driven, 
and successful – causes many healthcare professionals, policymakers, and the public at large 
to assume that Asian Americans do not experience health-related disparities. [15] This 
persistent stereotype contributes to a fundamental lack of cultural competency across 
healthcare institutions, leading to systemic barriers. Medical schools may insufficiently 
prepare clinicians for the unique health issues of Asian Americans or the cultural contexts in 
which these issues emerge, while hospitals may routinely overlook the service needs and 
challenges faced by Asian Americans. [23] Lack of culturally and linguistically tailored 
services, lack of health insurance, and lack of a usual care provider all pose significant 
systemic barriers to Asian American health seeking. [18]
In parallel, at the provider level, unconscious bias stemming from this stereotype, as well as 
from difficulties that providers may experience in communicating with Asian Americans 
with LEP and low acculturation, impacts screening and treatment recommendations.[18] 
Despite being aware of higher cancer rates among Asian Americans, providers may neglect 
to recommend cancer screening and prevention to this population. [24] Communication 
difficulties may also impact providers’ efforts to inform and educate Asian American 
patients about clinical trials that could offer novel treatments. Meanwhile, at the individual 
level, Asian Americans may hold negative views of Western medicine and a fatalistic 
acceptance of poor health.[18] These views, particularly when combined with some Asian 
Americans’ low health literacy and lack of familiarity with the health care system, may 
translate to a lack of skills needed to navigate the health system, or hesitation to ask pointed 
questions about cancer care and treatment options. Asian Americans have been shown to 
choose more aggressive treatment methods even when less aggressive options are presented 
to them. One study demonstrated that Chinese American and Japanese American women 
with early stage breast cancer chose mastectomies over breast-conserving therapies at higher 
rates than white American women due in part to the reluctance of Chinese American and 
Japanese American women to either burden or embarrass their providers by asking 
additional questions about treatment options. [25] Additionally, Asian Americans, like other 
racial/ethnic minority groups, may distrust government-administered scientific research.[17]
Strategies to reduce barriers at all levels have been tested and implemented successfully in 
various settings throughout the US, including small clinical settings as well as larger 
research environments, and often through partnerships between community-based Asian 
American providers and larger medical centers or universities. Adapting lessons learned 
from these interventions will improve cancer prevention and care for Asian Americans in 
general, and, more specifically, help to ensure the recruitment and retention of a diverse, 
successful million-person PMI cohort. For example, to improve cancer screening and care, 
one study found that inserting a prompt within the electronic health record could effectively 
remind clinicians to screen for HBV among Chinese and Vietnamese patients, thereby 
providing a pre-emptive solution to overcoming potential provider bias or error.[26] Other 
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studies have introduced culturally and linguistically tailored programming for Asian 
Americans, demonstrating that engaging and training lay health workers can significantly 
increase cervical and breast cancer screening rates among Vietnamese Americans, a method 
that may be even more effective when combined with media-based education.[27] Multi-
faceted clinic-based interventions that involve health educators from the community of 
interest have also been shown to be effective at increasing colorectal cancer screening rates 
among Chinese Americans. [28]
Recommendations
As precision medicine focuses attention on developing clinical trials and prevention research 
to explore molecular therapies, pharmaceutical options, and public health strategies to 
prevent and treat cancer among the groups who most need them, a critical opportunity to 
include Asian Americans and other racial/ethnic minority groups in the million-person 
cohort alongside is emerging. However, to realize this inclusive vision, developing 
innovative partnerships between researchers, clinicians, public health practitioners, 
policymakers, and the community will be essential, as will targeted efforts to dispel the 
model minority stereotype at the societal, systemic, and provider levels.
Key recommendations include:
• Improve data collection strategies to recruit sufficient numbers of Asian 
Americans to ensure a diverse cohort, and employ methods to enhance data 
analysis for Asian American participants. Previously published recommendations 
must be incorporated into new trial designs and analysis procedures, such as 
employing CBPR insofar as possible, recording granular ethnicity data in 
citywide, regional, and national surveys (including country of birth and years in 
the US), pooling data across years when necessary, and introducing other 
innovative methods.
• Improve provider education and training about Asian American cancer rates, as 
well as the social and cultural factors that impact their cancer risk. Addressing 
potential unconscious bias among providers, increasing providers’ cultural 
competency, and enhancing the structural competency of the health system 
overall is essential to effective participant outreach and recruitment. Efforts to 
advance cultural competency within medical and nursing schools, healthcare 
institutions, and research centers are critical.
• Ensure that linguistically and culturally appropriate health services, health 
information, trial recruitment materials, and community-based support are 
available to the diverse Asian American populations that need them. Strategies 
must include, but are not limited to, ensuring the development of linkages to 
community-based organizations serving Asian Americans that can inform 
recruitment and retention efforts; engagement and training of on-site patient 
navigators and/or community health workers to facilitate care for Asian 
American patients; availability of on-demand translation services in multiple 
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Asian languages; and implementation of changes to the physical medical facility, 
such as on-site signage, to enhance access for Asian Americans.
Operationalizing these recommendations will help to ensure the design and implementation 
of meaningful studies that engage Asian American patients in research over the long term. 
Only through such focused efforts will the PMI impact Asian American health disparities, 
and, more broadly, achieve its goal of personalized medicine for all Americans.
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